Editorial
Copyright ©The Author(s) 2017.
World J Diabetes. Jul 15, 2017; 8(7): 311-316
Published online Jul 15, 2017. doi: 10.4239/wjd.v8.i7.311
Figure 1
Figure 1 The effect of proprotein convertase subtilisin/kexin type 9 (A) and proprotein convertase subtilisin/kexin type 9 inhibition (B) on liver cells low-density lipoprotein receptors expression and serum low-density lipoprotein-cholesterol levels. PCSK9: Proprotein convertase subtilisin/kexin type 9; LDL: Low-density lipoprotein; LDLR: Low-density lipoprotein receptors.